Retrophin (RTRX) Misses Q4 EPS by 13c, Says Phase 3 Trial of Sparsentan in FSGS to Initiate in Second Half of 2017
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
Retrophin Provides Sparsentan Regulatory Update; Reports Fourth Quarter and Full Year 2016 Financial Results
March 1, 2017 4:02 PM ESTPhase 3 trial of sparsentan in FSGS to initiate in second half of 2017; Interim analysis of proteinuria to serve as basis for NDA filing for accelerated approval
Full year 2016 revenue grew 34% over 2015 to $134 million
Conference call today at 5:00 p.m. ET
SAN DIEGO, March 01, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today provided an update on the regulatory pathway for its late-stage product candidate sparsentan, and announced fourth quarter and full year 2016 financial results. Following... More
